Update: A frustrating summer
Omega’s H115 trading statement reports a delay in Visitect. There was a 2% rise in revenues in H1 to £5.69m despite a -£0.25m currency effect, without which the increase would have been 6.2%. Normalised H1 PBT was £0.56m, up 30%. Cash was not disclosed but capitalised costs may be more than expected over FY15. Edison has revised its FY15 and FY16 forecasts to reflect the available H1 figures and Visitect development schedule: a further Kenyan trial is planned for the first half of 2015. Allergy iSYS development is proceeding steadily with 16 tests having a finalised data package and 11 ready for validation. About 40 tests are needed for launch.Omega Diagnostics Group is a holding company. Through its subsidiaries, Co. is engaged in the manufacturing, development and distribution of medical diagnostics products. Co. has three operating divisions: Allergy and autoimmune, which in the research, development, production and marketing of in-vitro allergy and autoimmune tests; Food intolerance, which provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer; and Infectious disease and Other, which comprise of research, development, production and marketing of kits to aid the diagnosis of infectious diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.